Objective
to compare TAVI with surgical AVR in patients at low surgical risk
Study
prospective, multicentre, non-blinded, non-inferiority, randomised trial
Population
severe aortic steosis + predicted 30-day mortality <3%
Endpoints
composite of death or disabling stroke at 24 months, using Bayesian methods
Conclusion
TAVR with a self-expanding supraannular bioprosthesis was noninferior to surgery with respect to the composite end point of death or disabling stroke at 24 months
Popma et al. N Engl J Med. 2019;380:1706-15
